Menu
No Current Cure
Neovascular Age Related Macular Degeneration (AMD) is a progressive eye disease that leads to severe vision loss, and currently, there is no cure.
Non-Invasive Treatment
The existing treatment options for Neovascular AMD are invasive, often requiring injections into the eye, which can be uncomfortable and deter patient compliance. XP37 offers a non-invasive alternative to current therapies, as it is administered as eye drops rather than injections.
Targets the Posterior Segment
XP37 is specifically designed to target the posterior segment of the eye, the critical area affected by Neovascular AMD, addressing the root causes of exudation, potentially halting the progression and improving patient outcomes
The inability to see at night is one of the earliest symptoms of AMD.
While Neovascular AMD, the advanced form of AMD is approximately 10% of the cases, it accounts for nearly 90% of blindness caused by the disease. The estimated population of those suffering from AMD worldwide was 196 million in 2020, projected to increase to 288 million by 2040 due to largely increasing lifespan globally and Westernization of diet and lifestyle.
Neovascular Age-related macular degeneration (AMD) is a debilitating condition for which there is currently no cure. Even the available palliative treatments are limited and often come with significant drawbacks. These treatments can have numerous side effects, are expensive. As a result, patients suffering from AMD face a dramatic loss of autonomy and quality of life, which in turn increases the burden on healthcare systems and long-term care facilities.
XP37 eye drops, an innovative treatment currently in development to combat AMD, work by targeting the posterior segment of the eye and blocking adenosine receptors. This action leads to a reduction in the expression of VEGF (vascular endothelial growth factor), a critical factor in the progression of AMD. By decreasing VEGF levels, XP37 helps to reduce inflammation and neovascularization—the growth of new, abnormal blood vessels. These abnormal vessels often leak serous fluid and blood into the subretinal space, exacerbating vision loss. By targeting these mechanisms, XP37 has the potential to prevent exudation and improve outcomes for AMD patients, offering hope for better management of this challenging condition.
Neovascular AMD is a prevalent eye disorder that can severely impair visual function. This condition often leads to sight-threatening complications, including massive subretinal hemorrhage, vitreous hemorrhage, retinal pigment epithelium tears, macular atrophy, and macular scarring. These complications can have a profound impact on both short- and long-term vision, often resulting in significant vision loss. Tragically, many of these complications remain difficult to treat effectively, posing a major challenge for patients and healthcare providers alike. Early detection and proactive management are crucial in mitigating the effects of this debilitating disease and preserving vision.